Cellyan Biotechnology Co., Ltd Class A

Stage 4 · Declining · week 46

As of Oct 22, 2026, Cellyan Biotechnology is in Stage 4, the downtrend phase, now in week 46 (since Nov 21, 2025). It closed at $0.10, 94.4% below its 52-week high and below its 200-day average, which is falling.

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. More about the company

$0.10

-5.88% today

$4.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is HKPD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-01-15 → 2026-10-22

S? 41w

S4 48w

2025-01-152026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S1 3w → S4 48w current

Total tracked: 92 weeks across 3 stage runs.

HKPD among Medical Distribution10th of 11 by relative strength

All 11 →

Stocks in Medical Distribution ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	FOCLEDAP TMS S.A.	Stage 4 · wk 1	92	−12.4%
2	CAHCardinal Health, Inc.	Stage 2 · wk 1	90	+15.8%
3	HSICHenry Schein, Inc.	Stage 3 · wk 1	79	+1.1%
4	MCKMcKesson Corporation	Stage 2 · wk 7	76	+15.0%
5	CORCencora, Inc.	Stage 2 · wk 4	58	+8.4%
6	AHGAkso Health Group	Stage 4 · wk 16	36	+58.4%
7	YI111, Inc.	Stage 4 · wk 16	32	−17.3%
8	COSMCosmos Health Inc.	Stage 1 · wk 7	13	−37.8%
…10	HKPDCellyan Biotechnology Co., Ltd Class A	Stage 4 · wk 46	6	−19.3%

vs 52W High

-94.4%

$0.10 lo$1.71 hi

94.4% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 46

1w13w26w

Week 46, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-80.3%

200 DMA: $0.49 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.28x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.3%

-73.7%

-84.6%

YTD

-88.1%

-91.9%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 46 · Vol 1.28x

2026-10-21S4

Wk 46 · Vol 0.68x

2026-10-20S4

Wk 46 · Vol 0.04x

2026-10-19S4

Wk 46 · Vol 0.06x

2026-10-16S4

Wk 46 · Vol 0.06x

2026-10-15S4

Wk 45 · Vol 0.04x

2026-10-14S4

Wk 45 · Vol 0.06x

2026-10-13S4

Wk 45 · Vol 0.02x

2026-10-12S4

Wk 45 · Vol 0.06x

2026-10-09S4

Wk 45 · Vol 0.09x

2026-10-08S4

Wk 44 · Vol 0.14x

2026-10-07S4

Wk 44 · Vol 0.10x

Moving averages & range

50 DMA

$0.19

200 DMA

$0.49

52W High

$1.71

52W Low

$0.10

5D Low

$0.10

Resistance levels (recent highs)

20d High

$0.12

60d High

$0.44

120d High

$0.68

250d High

$1.44

Next resistance

+20.8%

to 20d High

ROE

-15.6%

Profit margin -8.5%

Dividend Yield

0.00%

P/B 0.2

Cellyan Biotechnology: quick answers

What stage is Cellyan Biotechnology in?

As of Oct 22, 2026, Cellyan Biotechnology (HKPD) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 21, 2025 and is in week 46. What the four stages mean

Is Cellyan Biotechnology in an uptrend?

No. Cellyan Biotechnology is in a Stage 4 downtrend. It trades 80.3% below its 200-day average, which is falling.

How far is Cellyan Biotechnology from its 52-week high?

Cellyan Biotechnology closed at $0.10 on Oct 22, 2026, 94.4% below its 52-week high of $1.71. Its 52-week low is $0.10.

How has Cellyan Biotechnology performed over the past year?

As of Oct 22, 2026, Cellyan Biotechnology is down 91.9% over the past year and down 88.1% so far in 2026.

Which sector and industry is Cellyan Biotechnology in?

Cellyan Biotechnology is in the Medical Distribution industry, part of the Health Care sector.

About this companyHealth Care· Medical Distribution

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.